Last reviewed · How we verify

NCT05659784: VAST-rehab

Virtually Assisted Home Rehabilitation After Acute STroke (VAST-rehab)

Completed NA Last updated 23 February 2024
What this trial tests

NA trial testing Telerehabilitation in Stroke in 20 participants. Completed in 8 May 2023.

Timeline
20 April 2020
Primary endpoint
8 May 2023
8 May 2023

Quick facts

Lead sponsorThe University of Texas Health Science Center, Houston
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date20 April 2020
Primary completion8 May 2023
Estimated completion8 May 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

The University of Texas Health Science Center, Houston

Who can join

18 and older, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the feasibility of a virtual education and virtual visit program in engaging patients with rehabilitation at home after stroke.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Virtually assisted home rehabilitation after acute stroke (VAST-rehab): A descriptive pilot study for young and underserved stroke survivors.
    Stevens EA, Muraly N, Da Silva CP, Richards L, et al · · 2025 · PMID 40103648 · DOI 10.1177/20552076251324443

Verify or expand the search:

Other trials of Telerehabilitation

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other The University of Texas Health Science Center, Houston trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05659784.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing